CXCR4 and hematologic disorder: Plerixafor (AMD3100) is a specific CXCR4 inhibitor approved by the Food and Drug Administration (FDA, USA) as a CXCR4-targeted therapy for hematopoietic stem cell mobilization in hematological malignancies [13].